ACR Late-breaking Abstract Poster Session

Session Type: ACR Late Breaking Abstracts
Tuesday, November 8, 2011: 9:00 AM-6:00 PM
Hall F2 - Poster Hall (McCormick Place West)
Talks:
Low Disease Activity or Remission Induction with Etanercept 50 Mg and Methotrexate in Moderately Active Rheumatoid Arthritis: Maintenance of Response and Safety of Etanercept 50 Mg, 25 Mg, or Placebo in Combination with Methotrexate in a Randomized Double-Blind Study
Josef S. Smolen1, Elena Ilivanova2, Stephen Hall3, Fedra Irazoque-Palazuelos4, Min-Chan Park5, Sameer Kotak6, Constance Hammond6, Ronald Pedersen6, Annette Szumski6, Andrew S. Koenig6 and Bonnie Vlahos6, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2Leningradskaya Regional Clinical Hospital, St.Petersburg, Russia, 3Emeritus Research, Malvern East, Australia, 4Hospital Mocel, Mexico City, Mexico, 5Yonse University College of Medicine, Seoul, South Korea, 6Pfizer Inc., Collegeville, PA
Sarilumab for the Treatment of Moderate-to-Severe Rheumatoid Arthritis: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, International Study
Mark C. Genovese, Stanford University Medical Center, Palo Alto, CA, Alan J. Kivitz, Altoona Center for Clinical Research, Duncansville, PA, J. Abraham Simon Campos, Centro De Especialidades Médicas, Merida, Mexico, Maria Rell-Bakalarska, Rheumatology and Osteoporosis Outpatient Clinic, Warsaw, Poland, Roy M. Fleischmann, Metroplex Clinical Research Center, Dallas, TX, Martine Jasson, Sanofi, Paris, France, Allen R. Radin, Regeneron Pharmaceuticals Inc, Tarrytown, NY, Xiaohong Huang, Sanofi, Bridgewater, NJ and Tom W. J. Huizinga, Leiden University Medical Centre, Leiden, Netherlands
Dose Ranging Study of VX-509, An Oral Selective JAK3 Inhibitor, As Monotherapy in Patients with Active Rheumatoid Arthritis (RA)
Roy Fleischmann1, George T. Spencer-Green2, Frank Fan2, Biliana Frankovic2, Xia Luo2, Thomas Hoock2 and Nemanja Damjanov3, 1University of Texas Southwestern Medical Center, Dallas, TX, 2Vertex Pharmaceuticals, Cambridge, MA, 3Institute of Rheumatology, Belgrade, Serbia
Concordance Between Enzyme-Linked Immunoassay and Multiplex Immunoassay for the Assessment of Anti-Double Stranded DNA Antibodies
Megan L. Krause, Robin M. Karras, Cynthia S. Crowson, David L. Murray, Melissa R. Snyder and Kevin G. Moder, Mayo Clinic, Rochester, MN
Efficacy and Safety of Subcutaneous Recombinant Chaperonin10 in Patients with Active Rheumatoid Arthritis Despite Methotrexate Treatment
P. T. Nash1, S. Hall2, V. Strand3, E. Kartvelishvili4, L. Kilasonia5, B. Williams6, C. Dobbin6 and D. Vanags6, 1University of Queensland, Brisbane, Australia, 2Melbourne Rheumatology, Melbourne, Australia, 3Stanford University, Palo Alto, CA, 4Ltd Academician V Tsitlanadze Scientific, Tblisis, Georgia, 5'Ltd' Medulla Chemotherapy and Immunotherapy Clinic, Tbilisi, Georgia, 6CBio Ltd, Brisbane, Australia
Is Centre-Based Rehabilitation Superior to Home-Based Rehabilitation After Knee Replacement? A Single-Blind, Randomised Controlled Trial
Victoria W.M. Ko1, Justine M. Naylor1, Ian A. Harris1, Anthony E.T. Yeo2 and Jack Crosbie3, 1University of New South Wales, Sydney, Australia, 2Ingham Institute Applied Medical Research, Sydney, Australia, 3The University of Sydney, Sydney, Australia
See more of: ACR Late Breaking Abstracts

To see other sessions for this day, use the date buttons to the left.